GWAS cohort demographics
| . | MPN cases . | Population controls . | V617F carriers . |
|---|---|---|---|
| N | 726 (100.0%) | 252 637 (100.0%) | 497 (100.0%) |
| Sex | |||
| Male | 223 (30.7%) | 138 608 (54.9%) | 295 (59.4%) |
| Female | 503 (69.3%) | 114 029 (45.1%) | 202 (40.6%) |
| Age | |||
| 1-30 | 17 (2.3%) | 35 149 (13.9%) | 11 (2.2%) |
| 31-45 | 120 (16.5%) | 74 166 (29.4%) | 45 (9.1%) |
| 46-60 | 290 (39.9%) | 66 390 (26.3%) | 91 (18.3%) |
| 61-112 | 299 (41.2%) | 76 932 (30.5%) | 350 (70.4%) |
| V617F self-reported status | |||
| N/A | 273 (37.6%) | ||
| V617F− | 92 (12.7%) | ||
| V617F+ | 361 (49.7%) |
| . | MPN cases . | Population controls . | V617F carriers . |
|---|---|---|---|
| N | 726 (100.0%) | 252 637 (100.0%) | 497 (100.0%) |
| Sex | |||
| Male | 223 (30.7%) | 138 608 (54.9%) | 295 (59.4%) |
| Female | 503 (69.3%) | 114 029 (45.1%) | 202 (40.6%) |
| Age | |||
| 1-30 | 17 (2.3%) | 35 149 (13.9%) | 11 (2.2%) |
| 31-45 | 120 (16.5%) | 74 166 (29.4%) | 45 (9.1%) |
| 46-60 | 290 (39.9%) | 66 390 (26.3%) | 91 (18.3%) |
| 61-112 | 299 (41.2%) | 76 932 (30.5%) | 350 (70.4%) |
| V617F self-reported status | |||
| N/A | 273 (37.6%) | ||
| V617F− | 92 (12.7%) | ||
| V617F+ | 361 (49.7%) |